Envista (NVST)
(Delayed Data from NYSE)
$17.70 USD
-0.14 (-0.78%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $17.70 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.70 USD
-0.14 (-0.78%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $17.70 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth B Momentum B VGM
Zacks News
Envista (NVST) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of 9.52% and 2.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Envista (NVST) Could Beat Earnings Estimates Again
by Zacks Equity Research
Envista (NVST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Envista (NVST) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Envista (NVST) Gets FDA 510 (k) Approval for N1 Implant System
by Zacks Equity Research
Envista (NVST) noted that the Nobel Biocare N1 system represents a significant step further in patient-centric dental implant solutions.
New Strong Sell Stocks for December 6th
by Zacks Equity Research
BYND, NVST, FSTR, ZBH, and PHR have been added to the Zacks Rank #5 (Strong Sell) List on December 6, 2021.
New Strong Sell Stocks for November 29th
by Zacks Equity Research
DVA, NVST, WWD, PHR, and ROAD have been added to the Zacks Rank #5 (Strong Sell) List on November 29, 2021
Envista (NVST) Q3 Earnings Beat Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of 12.50% and -10.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Envista (NVST) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Veeva Systems' (VEEV) Deal to Enhance Digital Clinical Trials
by Zacks Equity Research
Veeva Systems' (VEEV) partnership with Leo Pharma to significantly boost the clinical trial process for patients, sites and sponsors.
Here's Why You Should Hold on to NextGen (NXGN) Stock Now
by Zacks Equity Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. However, intense competition woes linger.
Here's Why You Should Add Neogen (NEOG) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG) on strength in its Food Safety and Animal Safety business segments.
Thermo Fisher (TMO) Expands Biologics Network With New Facility
by Zacks Equity Research
Thermo Fisher's (TMO) Lengnau site will offer biopharma companies a pathway from development to large-scale production.
Here's Why You Should Retain CVS Health (CVS) Stock For Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on growth in the company's specialty digital solutions and a bullish 2021 outlook.
Bio Rad (BIO) Global Growth Strong, Expenses Continue to Rise
by Zacks Equity Research
Bio Rad (BIO) is witnessing strong growth in the biopharma market, riding on the Droplet Digital PCR platform.
Here's Why You Should Invest in Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business.
Cardinal Health's (CAH) Unit to Aid Canadian Healthcare System
by Zacks Equity Research
Cardinal Health's (CAH) subsidiary to support the Canadian Healthcare system against COVID-19 with vaccination policy.
Cardiovascular Systems (CSII) Treats 1st Patient With ViperCross
by Zacks Equity Research
Cardiovascular Systems' (CSII) ViperCross offers the correct balance of support and flexibility to navigate tortuous anatomy and cross challenging lesions.
Here's Why You Should Invest in West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.
PacBio (PACB) Partners with ERGA, Boosts Biodiversity Research
by Zacks Equity Research
PacBio's (PACB) collaboration with ERGA will help scientists to take the first important step toward creating high-quality genetic maps of each plant and animal species in a reliable manner.
Quest Diagnostics' (DGX) Base Volumes Rise, Testing Recovers
by Zacks Equity Research
Contributions from new hospital lab management contracts as well as people returning to the healthcare system aid Quest Diagnostics (DGX).
Medtronic (MDT) Gets CE Mark for Radial Artery Access Portfolio
by Zacks Equity Research
Medtronic's (MDT) Rist Radial Access Catheters are indicated for the introduction of interventional devices into the peripheral, coronary and neuro vasculature.
NEOGEN (NEOG) Inks Genomic Selection Deal With Hendrix
by Zacks Equity Research
Hendrix Genetics with the help of NEOGEN's (NEOG) Genomics will be able to genotype the elite animals in the population.
Here's Why You Should Invest in Quest Diagnostics (DGX) Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) backed by its strong second-quarter performance and recovery in the base testing business.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Medtronic (MDT) owing to new product flow and strong market share gain across the company's businesses.
Medtronic (MDT) Hugo RAS System Used for 1st Clinical Procedure
by Zacks Equity Research
Medtronic's (MDT) Hugo RAS system is a modular, multi-quadrant platform intended for a broad range of soft-tissue procedures.